Chiral Interface of Amyloid Beta (Aβ): Relevance to Protein Aging, Aggregation and Neurodegeneration

Victor V. Dyakin¹,*, Thomas M. Wisniewski², Abel Lajtha¹
¹Departments: Virtual Reality Perception Lab. (VV. Dyakin) and Center for Neurochemistry (A. Lajtha), The Nathan S. Kline Institute for Psychiatric Research (NKI), Orangeburg, NY 10962, USA;
²Departments of Neurology, Pathology and Psychiatry, Center for Cognitive Neurology, New York University School of Medicine, New York, NY 10016, USA;

Abstract

Biochirality is the subject of distinct branches of science, including biophysics, biochemistry, the stereochirality of protein folding, neuroscience, brain functional laterality and bioinformatics. At the protein level, biochirality is closely associated with various post-translational modifications (PTMs) accompanied by the non-equilibrium phase transitions (PhTs NE). PTMs NE support the dynamic balance of the prevalent chirality of enzymes and their substrates. The stereoselective nature of most biochemical reactions is evident in the enzymatic (Enz) and spontaneous (Sp) PTMs (PTMs Enz and PTMs Sp) of proteins. Protein chirality, which embraces biophysics and biochemistry, is a subject of this review. In this broad field, we focus attention to the amyloid-beta (Aβ) peptide, known for its essential cellular functions and associations with neuropathology. The widely discussed amyloid cascade hypothesis (ACH) of Alzheimer’s disease (AD) states that disease pathogenesis is initiated by the oligomerization and subsequent aggregation of the Aβ peptide into plaques. The racemization-induced aggregation of protein and RNA have been extensively studied in the search for the contribution of spontaneous stochastic stereo-specific mechanisms that are common for both kinds of biomolecules. The failure of numerous Aβ drug-targeting therapies requires the reconsolidation of the ACH with the concept of PTMs Sp. The progress in methods of chiral discrimination can help overcome previous limitations in the understanding of AD pathogenesis. The primary target of attention becomes the network of stereospecific PTMs that affect the aggregation of many pathogenic agents, including Aβ. Extensive recent experimental results describe the truncated, isomerized and racemized forms of Aβ and the interplay between enzymatic and PTMs Sp. Currently, accumulated data suggest that non-enzymatic PTMs Sp occur in parallel to an existing metabolic network of enzymatic pathways, meaning that the presence and activity of enzymes does not prevent non-enzymatic reactions from

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Correspondence: Victor.dyakin@nki.rfmh.org.

Author Contributions: V.V.D. contribute to review of biophysical aspect of molecular chirality, PTMs, protein aggregation, and neurodegeneration. A.L. contribute to review of biochemical aspect of molecular chirality, PTMs, protein aggregation, and neurodegeneration. T.M.W. contributed to review of biochemical aspects of PTMs, protein aggregation and neurodegeneration. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.
occurring. PTMs $^{Sp}$ impact the functions of many proteins and peptides, including Aβ. This is in logical agreement with the silently accepted racemization hypothesis of protein aggregation (RHPA). Therefore, the ACH of AD should be complemented by the concept of PTMs $^{Sp}$ and RHPA.

**Keywords**

biochirality; post-translational modifications; protein folding; protein aggregation; spontaneous chemical reactions; neurodegeneration; non-equilibrium phase transitions

---

1. Introduction

The amyloid cascade hypothesis (ACH) has played a crucial role in the understanding of the Alzheimer’s disease (AD) etiology and pathogenesis. The deposition of β-amyloid (Aβ) and neurofibrillary tangles (NFTs) traditionally served as the essential neuropathological features of AD. However, for many years, the attention to the stereochemistry of underlying spontaneous events was under-appreciated. Stereochemical errors in biomolecular structures, including proteins and peptides, have a dramatic impact on cell physiology [1]. The discovery of free D-aspartic acid (D-Asp) in rodents and man open a new window for understanding the mechanisms of protein synthesis and degradation [2]. Proteins, including glycoproteins, are the subjects of the reversible enzymatic (Enz) [3] and irreversible spontaneous (Sp) [4] post-translational modifications (PTMs $^{Enz}$ and PTMs $^{Sp}$). (see Figure 1). All physiological and pathological forms of proteins are the consequence of PTMs. We are focusing on the aberrant forms of PTM, such as racemization $^{Sp}$ and isomerization $^{Sp}$. The relevance of the spontaneous modifications of amino acids (AAs) within peptides and long-lived proteins to protein aging, accumulation and pathologies is being increasingly recognized in the recent studies. Accordingly, the primarily biomarkers of aging and neurodegeneration are becoming the protein-cell-specific PTMs $^{Sp}$ of amino acids (AAs) [5–50].

2. Racemization of the Aβ

With the recognition of the fact that many proteins (Aβ, TAU, prion protein Prion (PrP), Huntingtin and α-synuclein) are the substrate of the aggregation-prone PTMs $^{Sp}$ [51], we are focusing, primarily, on the racemization of the Aβ. The amyloid precursor protein (APP) is one of the most studied proteins concerning pathological misfolding. The products of APP processing by α-, β- and γ-secretases range from 16 to 49 AAs.

Most studied amyloid beta (Aβ) peptides includes Aβ (1–16), Aβ (1–19), Aβ (20–34), Aβ (20–33), Aβ (20–40), Aβ (23–34), Aβ (34–40), Aβ (35–40), Aβ (1–35), Aβ (1–40) and Aβ (1–42) [5,52] are characterized by differential chain of PTMs and susceptibility to PTMs $^{Sp}$. PTMs of Aβ (1–42), the primary constituent of Aβ plaques in the AD brain, are extensively studied. Misfolding and aggregation of Aβ peptides is the convincing example of a link between the perturbations of the molecular chirality, deteriorated enzyme-substrate recognition, abnormal cell signaling (including neurotransmission) and cognitive dysfunction [3]. The spontaneous aggregation of Aβ peptides into amyloid plaques and in
the walls of the cerebral vasculature is the unresolved issue of Alzheimer’s disease (AD)-amyloid conundrum [6]. It is a common assumption that PTMs Sp can significantly alter the structure of the original polypeptide chain. The AAs that most frequently undergo racemization Sp and isomerization Sp in human proteins are aspartate (Asp), asparagine (Asn), glutamate (Glu), glutamine (Glu), serine (Ser), alanine (Ala) and proline [7]. For Aβ peptides, racemization-prone are found two non-essential AAs: serine (Ser) and aspartate (Asp) (Aβ-42 contains two Ser and three Asp residues (see Table 1)). For Asp, the mechanism acceleration of racemization Sp (about 10^5) is associated with the specific succinimide intermediates [8–10]. Both D-Ser and D-Asp play a crucial role in N-methyl-d-aspartate (NMDA) receptor-mediated neurotransmission. D-Ser26-Aβ1–40 possesses a strong tendency to form fibrils [11]. AD patients have increased brain D-Ser levels [12]. This fact agrees with the activated spontaneous racemization (RsSp) of Ser residue in Aβ, with an elevated level of D-Ser in amyloid plaques, impairment of the NMDA neurotransmission, memory loss and cognitive dysfunction. Racemization and isomerization of Asp are the most common types of non-enzymatic covalent modification that leads to an accumulation of aging proteins in numerous human tissues [13]. Asp-1, Asp-7 and Asp-23 of Aβ are crucial in the control of Aβ aging and aggregation [5].

Residues Asp-1 and Asp-7 of Aβ in amyloid plaques are a mixture of L-, D-, L-iso- and D-iso-aspartate [14]. D-Asp-7 enhances the aggregation process by shifting the equilibrium of Aβ from the soluble to the insoluble form [15]. Therefore, the set of PTMs Sp, including racemization Sp and isomerization Sp, is an efficient modifier of Aβ metabolism. In 2011, Kumar promoted the hypothesis that enzymatic phosphorylation of Aβ triggers the formation of toxic aggregates [16], which has been confirmed by later studies [3]. In 1994, Szendrei discovered that spontaneous isomerization of Asp affects the conformations of synthetic peptides [17]. However, the role of the PTMs Sp in Aβ aggregation and neurotoxicity remains in the shadow. Consequently, many structural details of misfolded Aβ have remained elusive for a long time [7,18]. This short review provides a summary of information regarding events of PTMs Sp in Aβ. The heterogeneity of Aβ proteolytic forms in AD brain is represented by at least 26 unique peptides, characterized by various N- and C-terminal truncations. The N- and C-terminal truncated fragments (in contrast to canonical Aβ) are allowing to distinguish between the soluble and insoluble aggregates. The N-terminal truncations are predominating in the insoluble material and C-terminal truncations segregating in the soluble aggregates [19,20]. Aβ peptides exhibit a high sensitivity of the secondary structure and fibril morphologies to the chirality of ligands [21] and enzymes of PTMs. Only for a small part of Aβ isoforms exist information regarding the pathways of PTMs Sp.

Currently, available data for Aβ42 peptides are summarized in Tables 1–3. The data in Tables 2 and 3 demonstrate two essential facts: first, the coincidence of phosphorylation and spontaneous racemization/isomerization (enzymatic phosphorylation can be accompanied by the enzyme-driven or spontaneous racemization) events at the Ser-8, Ser-26 (Ser-26 residue is located within the turn region of Aβ), and Asp23 residues, second, currently available information covering the PTMs Sp of Aβ is limited only to 4 from the 16 types of AAs, which means that much remains to be explored. Most recent attempts to overcome previous limitations of the ACH are concentrated on many additional essential aspects of metabolism,
contributing to progress in understanding [22–42]. However, most of them, do not pay enough
attention to the stereochemistry of the PTM in general and the impact of spontaneous
racemization ($Sp$) on $\beta$ assembly, aggregation and functions. At the same time, the progress
in methods of chiral discrimination has produced new, stereochemistry-oriented,
experimental results regarding aberrant PTMs $Sp$. Growing evidence suggests that proteins
undergo several unusual, previously unknown PTMs associates with the interplay between
physiological protein modification, spontaneous aging-associated molecular processes
[7, 10, 11, 13], stress conditions [23, 24], accidental co-localization of the enzyme and
substrate or PTMs $Sp$. For $\beta$, Asp and Ser are known as the most racemization prone
residues. For the illustration purpose, we provide several of many existing molecular
pathways where the racemization $Sp$ of Ser can be critical.

First, the pathological role of mitochondrial enzymes Ser proteases (SerPs) is attributed to
neurodegenerative disorders such as AD and Parkinson’s and disease [25–27]. The HtrA
(high-temperature requirement) family represents a class of oligomeric SerPs [25]. Its
members are classified by presence (in its AAs sequence) a catalytic triad contains His, Asp
and Ser residues known as racemization prone.

Second, chaperone signaling complexes in AD involve a wide range of heat shock proteins
(Hsp), including Hsp27, that are engaged in protection against $\beta$ aggregation and toxicity
[28]. Human Hsp27 is phosphorylated at three Ser residues (Ser15, Ser78 and Ser82), were
Ser-78 and Ser-82 are the major phosphorylation sites [29, 30]. It is evident that due to the
stereo-specificity activity of both protein types (SerPs and Hsps) racemization $Sp$ of Ser
resides in each of them will contribute to the aberrant processing of substrates, including
$\beta$, inducing the cascade of aggregation, accompanied by neurodegeneration. The
aggregation of protein and peptide indicates the decrease in the turnover rate. Accordingly,
the previously short half-life-proteins are changing in the direction toward the long-lived
one. Lowering turnover rate (i.e., protein aging) makes proteins the subject of the time-
dependent PTMs $Sp$, including oxidation, nitration, glycation, isomerization and
racemization [7]. The set of PTMs $Sp$ and its effect on protein polymerization both are
substrate specific. Tyrosine (Tyr) nitration, for example, significantly decreased the
aggregation of $\beta1$–40. [43].

3. Conclusions

In the manuscript, we assess the previous and current experimental results acquired in the
specific areas of chiral proteomics—$\beta$ folding—from a broad perspective. For this
purpose, we addressed the basic, fundamental and widely recognized facts and theories
underlying the stereochemistry of $\beta$. Due to progress in multidisciplinary fields, the view
of the origin of biologic non-equilibrium chirality evolves from the physico-chemical nature
of enantioselective autocatalytic reaction networks to a process that play an essential role in
the pathogenesis of AD [44]. The phenomena of biochirality embrace two undivided
branches of science biophysics and biochemistry. In 1990th, the nature of living organisms
was associated with the absolute homochirality [50]. With the discovery of D-AAs in living
organisms and the process of enzymic racemization, the concept of homochirality was
replaced by the notion of prevalent chirality.
In the language of entropy, the transfer of protein/solvent system from the state of low-entropy (racemic mixture) to the high-entropy state (homochirality) is the order-disorder type transitions.

In terms of thermodynamics, this is the transition from the non-equilibrium to the equilibrium state. Accordingly, the enzymic PTMs, from a biophysical perspective, is the set of physiological non-equilibrium phase transitions. Enzymic racemization is an essential and necessary source of D-AAs in organisms. In contrast, the spontaneous racemization, as an aberrant PTMs, is the window for the irreversible transfer from non-equilibrium to equilibrium conditions.

In the words of proteomics, irreversible racemization is the conformation of protein from functional (physiological) to the dis-functional (inert or toxic) state of protein solvent, aggregates and depositions. The universal significance of the symmetry constraints is evident from the viral to the human proteome. The biologic significance of racemization-induced protein aggregation for the neuropathogenesis of AD was experimentally demonstrated as early as 1994 [45]. Currently accumulated data about PTMs of many proteins and peptides, including Aβ are coherent with the silently accepted racemization hypothesis of protein aggregation (RHPA). Therefore, after “three decades of struggles, ACH [46] of the neurodegeneration should be complemented by the concept of PTMs Sp and non-equilibrium phase transitions (PhTs NE) [47–50].

Acknowledgments:

We gratefully thanks: Justin Lucas for criticism and correction. Csaba Vadasz for criticism and correction. Alexander G. Dadali for discussion of the thermodynamics of protein conformation, and Frank Fagnano for contribution to clarity of the argumentation.

Funding: This manuscript is supported by NIH grants AG060882, AF058267 and AG066512 to TMW.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ACH          | Amyloid cascade hypothesis |
| PTMs         | post-translational modifications |
| Enz PTMs     | Enz enzymic PTMs |
| Sp PTMs      | Sp spontaneous PTMs |
| PhTs NE      | NE non-equilibrium phase transitions |
| Aβ           | amyloid beta |
| RHPA         | racemization hypothesis of protein aggregation |
| Ala          | Alanine |
| Asn          | Asparagine |
| Ser          | Serine |

Symmetry (Basel). Author manuscript; available in PMC 2021 July 28.
| Reference |
|-----------|
| 1. Schreiner E; Trabuco LG; Freddolino PL; Schulten K Stereochemical errors and their implications for molecular dynamics simulations. BMC Bioinform 2011, 12, 190. |
| 2. Dunlop DS; Neidle A; McHale D; Dunlop DM; Lajtha A The presence of free D-aspartic acid in rodents and man. Biochem. Biophys. Res. Commun 1986, 141, 27–32. [PubMed: 3801000] |
| 3. Jamasbi E; Separovic F; Hossain MA; Ciccotosto GD Phosphorylation of a full-length amyloid-β peptide modulates its amyloid aggregation, cell binding and neurotoxic properties. Mol. BioSyst 2017, 13, 1545–1551. [PubMed: 28642958] |
| 4. Yokoyama H; Mizutani R; Noguchi S; Hayashida N Structural and biochemical basis of the formation of isospartate in the complementarity-determining region of antibody 64M-5 Fab. Sci. Rep 2019, 9, 18494. [PubMed: 31811216] |
| 5. Moro ML; Collins MJ; Cappellini E Alzheimer’s disease and amyloid β-peptide deposition in the brain: A matter of ‘aging’? Biochem. Soc. Trans 2010, 38, 539–544. [PubMed: 20298218] |
| 6. Roher AE; Kokjohn TA; Clarke SG; Sierks MR; Maarouf CL; Serrano GE; Sabbagh MS; Beach TG APP/Aβ structural diversity and Alzheimer’s disease pathogenesis. Neurochem. Int 2018, 110, 1–13. |
| 7. McCudden CR; Kraus VB Biochemistry of amino acid racemization and clinical application to musculoskeletal disease. Clin. Biochem 2006, 39, 1112–1130. [PubMed: 17046734] |
| 8. Radkiewicz IL; Zipse H; Clarke S; Houk KN Accelerated racemization of aspartic acid and asparagine residues via succinimide intermediates: An ab initio theoretical exploration of mechanism. J. Am. Chem. Soc 1996, 118, 9148–9155. |
| 9. Helfman PM; Bada JL; Shou MY Considerations on the role of aspartic acid racemization in the aging process. Gerontology 1977, 23, 419–425. [PubMed: 892449] |
| 10. Takahashi O; Kirikoshi R; Manabe N Academic editor Putz Mihai V. Racemization of the succinimide intermediate formed in proteins and peptides: A computational study of the mechanism catalyzed by dihydrogen phosphate ion. Int. J. Mol. Sci 2016, 10, 1698. |
| 11. Kubo T; Kumagae Y; Miller CA; Kaneko I Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer’s disease: Implications in the pathogenesis of Alzheimer’s disease. J. Neuropathol. Exp. Neurol 2003, 62, 248–259. [PubMed: 12638729] |
| 12. Madeira C; Lourenco MV; Vargas-Lopes C; Suemoto CK; Brandão CO; Reis T; Leite REP; Laks J; Jacob-Filho W; Pasqualucci CA D-serine levels in Alzheimer’s disease: Implications for novel biomarker development. Transl. Psychiatry 2015, 5, e561. [PubMed: 25942042] |
| 13. Ritz-Timme S; Collins MJ Racemization of aspartic acid in human proteins. Ageing Res. Rev 2002, 1, 43–59. [PubMed: 12039448] |
| 14. Roher AE; Yablensson JD; Clarke S; Wolkow C; Wang R; Cotter RJ; Readon IM; Zircher-Neely HA; Heinrikson RL; Ball MJ; et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J. Biol. Chem 1993, 268, 3072–3083. [PubMed: 8428986] |
| 15. Kuo YM; Webster S; Emmerling MR; de Lima N; Roher AE Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer’s disease. Biochim. Biophys. Acta 1998, 1406, 291–298. [PubMed: 9630681] |
| 16. Kumar S; Walter J Phosphorylation of amyloid beta (Aβ) peptides—A trigger for formation of toxic aggregates in Alzheimer’s disease. Aging 2011, 3, 803–812. [PubMed: 21869458] |

*Symmetry (Basel).* Author manuscript; available in PMC 2021 July 28.
17. Szendrei GI; Fabian H; Mantsh HH; Lovas S; Nyéki O; Schön I; Otvos L Aspartate-bond isomerization affects the major conformations of synthetic peptides. Eur. J. Biochem. FEBS 1994, 226, 917–924.

18. Xiao Y; Ma B; McElheny D; Parthasarathy S; Long F; Hoshi M; Nussinov R; Ishii Y Aβ (1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat. Struct. Mol. Biol 2015, 22, 499–505. [PubMed: 25938662]

19. Wildburger NC; Esparza TJ; LeDuc RD; Fellers RT; Thomas PM; Cairns NJ; Kelleher NL; Bateman RJ; David L; Brody DL Diversity of amyloid-beta proteoforms in the Alzheimer’s disease brain. Sci. Rep 2017, 7, 9520. [PubMed: 28842696]

20. Jiang N; Leithold LHE; Post J; Ziehm T; Maier J; Gremer M; Schartmann E; Shah NJ; Kutzsche J; et al. Preclinical pharmacokinetic studies of the tritium labelled D-enantiomeric peptide D3 developed for the treatment of Alzheimer’s disease. PLoS ONE 2015, 10, e0128553. [PubMed: 26046986]

21. Malishev R; Arad E; Bhunia SK; Shaham-Niv S; Kolusheva S; Gazit E; Jelinek R Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots. Chem. Commun 2018, 54, 7762–7765.

22. Zhou Y; Sun Y; Ma QH; Liu Y Alzheimer’s disease: Amyloid-based pathogenesis and potential therapies. Cell Stress 2018, 2, 150–161. [PubMed: 31225482]

23. Ravikiran B; Mahalakshmi R Unusual post-translational protein modifications: The benefits of sophistication. RSC Adv 2014, 4, 33958–33974.

24. Osna NA; Carter WG; Ganesan M; Kirpich IA; McClain CJ; Petersen DR; Shearn CT; Tomasi ML; Kharbanda KK Aberrant post-translational protein modifications in the pathogenesis of alcohol-induced liver injury. World J. Gastroenterol 2016, 22, 6192–6200. [PubMed: 27468209]

25. Grau S; Baldi A; Bussani R; Tian X; Stefanescu R; Przybylski M; Richards P; Jones SA; Shridhar V; Tim Clausen T; et al. Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc. Natl. Acad. Sci. USA 2005, 102, 6021–6026. [PubMed: 15855271]

26. Gieldon A; Zurawa-Janicka D; Jarzab M; Wenta T; Golik P; Dubin G; Lipinska B; Ciarkowski J Distinct 3D architecture and dynamics of the human Htr2(OMI) protease and its mutated variants. PLoS ONE 2016, 11, e0161526. [PubMed: 27571206]

27. Goo HG; Rhim H; Kang S Pathogenic role of serine protease HtrA2/Omi in neurodegenerative diseases. Curr. Protein Pept. Sci 2017, 18, 746–757. [PubMed: 26965693]

28. Singh MK; Sharma B; Tiwari PC The small heat shock protein Hsp27: Present understanding and future prospects. J. Therm. Biol 2017, 69, 149–154. [PubMed: 29037376]

29. Landry J; Lambert H; Zhou M; Lavoie JN; Hickey E; Weber LA; Anderson CW Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. J. Biol. Chem 1992, 267, 794–803. [PubMed: 1730670]

30. Tomiyama T; Asano S; Furiya Y; Shirasawa T; Endo N; Mori H Racemization of Asp 23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J. Biol. Chem 1994, 269, 10205–10208. [PubMed: 8144598]

31. Shimizu T; Fukuda H; Murayama S; Izumiya N; Shirasawa T Iso-aspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer’s disease. J. Neurosci. Res 2002, 70, 451–461. [PubMed: 12391606]

Symmetry (Basel). Author manuscript; available in PMC 2021 July 28.
37. Warmack RA; Boyer DR; Zee CT; Richards LR; Sawaya MR; Cascio D; Gonen T; Eisenberg DS; Clarke SG. Structure of A-β(20–34) with Alzheimer’s-associated isomerization at Asp23 reveals a distinct protofilament interface. Nat. Commun 2019, 10, 3357. [PubMed: 31350392]

38. Kumar S; Singh S; Hinze D; Josten M; Sahl HG; Siepmann M; Walter J. Phosphorylation of amyloid-β peptide at serine-8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. J. Biol. Chem 2012, 287, 8641–8651. [PubMed: 22267728]

39. Barykin EP; Petrushanko IY; Kozin SA; Telezi GB; Cherno AS; Lopina OD; Radko SP; Mitkevich VA; Makarov AM. Phosphorylation of the amyloid-beta peptide inhibits zinc-dependent aggregation, prevents Na,K-ATPase inhibition, and reduces cerebral plaque deposition. Front. Mol. Neurosci 2018, 11, 302. [PubMed: 30210292]

40. Rezaei-Ghaleh N; Amininasab M; Kumar S; Walter J; Zweckstetter M. Phosphorylation modifies the molecular stability of β-amyloid deposits. Nat. Commun 2016, 7, 11359. [PubMed: 27072999]

41. Milton NG. Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase. Neuroreport 2001, 12, 3839–3844. [PubMed: 11726805]

42. Kumar S; Wirths O; Stüber K; Wunderlich P; Theil S; Rezaei-Ghaleh N; Zweckstetter M; Bayer TA; Brüstle O; et al. Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol 2016, 131, 525–537. [PubMed: 26898910]

43. Zhao J; Wang P; Li H; Gao Z. Nitration of Y10 in Aβ1–40: Is it a compensatory reaction against oxidative/nitrative stress and Aβ aggregation? Chem. Res. Toxicol 2015, 28, 401–407. [PubMed: 25387246]

44. Ribó JM; Hochberg D. Concept Paper. Chemical basis of biological homochirality during the abiotic evolution stages on Earth. Symmetry 2019, 11, 814.

45. Mori H; Ishii K; Tomiyama T; Furiya Y; Sahara N; Asano N; Endo N; Shirasawa T; Takio K. Racemization: Its biological significance on neuropathogenesis of Alzheimer’s disease. Tohoku J. Exp. Med 1994, 174, 251–262. [PubMed: 7761990]

46. Kasim JK; Kavianinia I; Harris PWR; Brimble MA. Three decades of amyloid beta synthesis: Challenges and advances. Front. Chem 2019, 7, 472. [PubMed: 31334219]

47. Dyakin VV; Lucas J. Non-equilibrium phase transition in biochemical—Systems. Chain of chirality transfer as Determinant of Brain Functional Laterality. Relevance to Alzheimer disease and cognitive psychology. In Proceedings of the Alzheimer’s Association International Conference (AAIC-2017), London, UK, 16–20 July 2017.

48. Ornes S. Core concept: How nonequilibrium thermodynamics speaks to the mystery of life. Proc. Natl. Acad. Sci. USA 2017, 114, 423–424. [PubMed: 28096502]

49. Schrödinger E. What is Life? The Physical Aspect of the Living Cell; Cambridge University Press: Cambridge, UK, 1994.

50. Nansheng Z. The role of homochirality in evolution. In Advances in BioChirality; Zucchi C, Caglioti L, Palvi G, Eds.; Elsevier Science: Amsterdam, The Netherlands, 1999.

51. Hsu YH; Chen Y-W; Wu M-H; Tu LH. Protein glycation by glyoxal promotes amyloid formation by Islet Amyloid polypeptide. Biophys. J 2019, 116, 2304–2313. [PubMed: 3155148]

52. Zhang A; Qi W; Good TA; Fernandez EJ. Structural differences between Aβ(1–40) intermediate oligomers and fibrils elucidated by proteolytic fragmentation and hydrogen/deuterium exchange. Biophys. J 2009, 96, 1091–1104. [PubMed: 19186145]
Figure 1.
Spontaneous deamidation and isomerization of asparagine (Asn). Side-chain bonds of asparagine and aspartate are drawn as bold lines. Adopted from [4].
**Table 1.**

The frequency (f) of the AAs appearance in Aβ (1–42).

| f   | Amino Acids |
|-----|-------------|
| 6   | Gly  Val    |
| 4   | Ala         |
| 3   | Asp  Glu  Phe  His  Ile |
| 2   | Lys  Leu  Ser |
| 1   | Met  Asn  Arg  Gln  Tyr |
Table 2.

Coincidence of enzymatic and spontaneous PTMs at Ser and Asp residues of Aβ in the neurodegenerative amyloid aggregates.

| Peptide    | Disease | Residue | PTMs                      |
|------------|---------|---------|---------------------------|
|            |         |         | Rcm. | Ism. | Ph.     |
|            |         |         | Spontaneous | Enzymic |
| A-β (40–42) | AD      | Ser-8   | [24, 35] | [3, 40, 41, 42] |
| A-β (20–34) |         | Asp-23  | [35, 37, 38] | [40] |

Post-translational modification (PTMs): Spontaneous (Sp) and Enzymic (Enz), Racemization (Rcm), Isomerization (Ism), Phosphorylation (Ph).
Table 3.

Coincidence of phosphorylation and Asp residues of Aβ (1-42).

| A-Beta (1-12) | N-Terminal | C-Terminal |
|----------------|-------------|------------|
| Gly | Tyr | Glu | Val | His | His | Glu | Lys | Leu | Val | Phe | Phe | Ala | Glu | Asp | Val | Gly | Ser | Asn | Lys | Gly | Ala | Ile | Ile | Gly | Leu | Met | Val | Gly | Val | Val | Ile | Ala |
| Y | E | V | H | H | Q | K | L | V | F | F | A | E | D | V | G | S | N | K | G | A | I | I | G | L | M | V | G | G | V | V | I | A |

Symmetry (Basel). Author manuscript; available in PMC 2021 July 28.